Literature DB >> 22611470

Akt blocks the tumor suppressor activity of LKB1 by promoting phosphorylation-dependent nuclear retention through 14-3-3 proteins.

Ling Liu, Fung-Ming Siu, Chi-Ming Che, Aimin Xu, Yu Wang.   

Abstract

The survival kinase Akt and the tumor suppressor LKB1 elicit opposite effects on cell proliferation and tumorigenesis. The present study demonstrates that Akt acts as an upstream kinase of LKB1 to promote the phosphorylation at Ser334 and facilitate its binding to 14-3-3 proteins, resulting in a decreased interaction with STE20-related adaptor protein α (STRADα) and an enhanced nuclear accumulation of LKB1. The S334A mutant of LKB1 exhibits impaired binding with 14-3-3 proteins and is localized predominantly in the cytoplasm, whereas the phosphorylation-mimic mutant, S334D, is sequestrated in the nuclei and unable to elicit the tumor suppressor function. On the other hand, S334A exerts more potent activity than wild type LKB1 in inhibiting the breast cancer cell proliferation and tumor growth in mice. These findings suggest that Akt blocks the anti-growth signal of LKB1 by triggering a phosphorylation-dependent nuclear sequestration of LKB1 through 14-3-3 proteins.

Entities:  

Keywords:  14-3-3; Akt kinase; LKB1; nuclear/cytoplasmic shuttling; tumorigenesis

Year:  2012        PMID: 22611470      PMCID: PMC3353533     

Source DB:  PubMed          Journal:  Am J Transl Res        ISSN: 1943-8141            Impact factor:   4.060


  42 in total

1.  Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display.

Authors:  B Wang; H Yang; Y C Liu; T Jelinek; L Zhang; E Ruoslahti; H Fu
Journal:  Biochemistry       Date:  1999-09-21       Impact factor: 3.162

2.  Involvement of 14-3-3 proteins in nuclear localization of telomerase.

Authors:  H Seimiya; H Sawada; Y Muramatsu; M Shimizu; K Ohko; K Yamane; T Tsuruo
Journal:  EMBO J       Date:  2000-06-01       Impact factor: 11.598

Review 3.  Exploiting the PI3K/AKT pathway for cancer drug discovery.

Authors:  Bryan T Hennessy; Debra L Smith; Prahlad T Ram; Yiling Lu; Gordon B Mills
Journal:  Nat Rev Drug Discov       Date:  2005-12       Impact factor: 84.694

4.  SIRT1 promotes proliferation and prevents senescence through targeting LKB1 in primary porcine aortic endothelial cells.

Authors:  Yi Zu; Ling Liu; Mary Y K Lee; Cheng Xu; Yan Liang; Ricky Y Man; Paul M Vanhoutte; Yu Wang
Journal:  Circ Res       Date:  2010-03-04       Impact factor: 17.367

5.  Growth arrest by the LKB1 tumor suppressor: induction of p21(WAF1/CIP1).

Authors:  Marianne Tiainen; Kari Vaahtomeri; Antti Ylikorkala; Tomi P Mäkelä
Journal:  Hum Mol Genet       Date:  2002-06-15       Impact factor: 6.150

6.  14-3-3 sigma positively regulates p53 and suppresses tumor growth.

Authors:  Heng-Yin Yang; Yu-Ye Wen; Chih-Hsin Chen; Guillermina Lozano; Mong-Hong Lee
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

7.  Aberrant hyperactivation of akt and Mammalian target of rapamycin complex 1 signaling in sporadic chordomas.

Authors:  Sangyeul Han; Carolyn Polizzano; Gunnlaugur P Nielsen; Francis J Hornicek; Andrew E Rosenberg; Vijaya Ramesh
Journal:  Clin Cancer Res       Date:  2009-03-10       Impact factor: 12.531

Review 8.  LKB1 kinase: master and commander of metabolism and polarity.

Authors:  James Spicer; Alan Ashworth
Journal:  Curr Biol       Date:  2004-05-25       Impact factor: 10.834

Review 9.  LKB1-dependent signaling pathways.

Authors:  Dario R Alessi; Kei Sakamoto; Jose R Bayascas
Journal:  Annu Rev Biochem       Date:  2006       Impact factor: 23.643

10.  Adiponectin haploinsufficiency promotes mammary tumor development in MMTV-PyVT mice by modulation of phosphatase and tensin homolog activities.

Authors:  Janice B B Lam; Kim H M Chow; Aimin Xu; Karen S L Lam; Jing Liu; Nai-Sum Wong; Randall T Moon; Peter R Shepherd; Garth J S Cooper; Yu Wang
Journal:  PLoS One       Date:  2009-03-25       Impact factor: 3.240

View more
  10 in total

1.  KRT-232 and navitoclax enhance trametinib's anti-Cancer activity in non-small cell lung cancer patient-derived xenografts with KRAS mutations.

Authors:  Xiaoshan Zhang; Ran Zhang; Huiqin Chen; Li Wang; Chenghui Ren; Apar Pataer; Shuhong Wu; Qing H Meng; Min Jin Ha; Jeffrey Morris; Yuanxin Xi; Jing Wang; Jianhua Zhang; Don L Gibbons; John V Heymach; Funda Meric-Bernstam; John Minna; Stephen G Swisher; Jack A Roth; Bingliang Fang
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Deletion of MLIP (muscle-enriched A-type lamin-interacting protein) leads to cardiac hyperactivation of Akt/mammalian target of rapamycin (mTOR) and impaired cardiac adaptation.

Authors:  Marie-Elodie Cattin; Jessica Wang; Jonathan J Weldrick; Cassandra L Roeske; Esther Mak; Stephanie L Thorn; Jean N DaSilva; Yibin Wang; Aldon J Lusis; Patrick G Burgon
Journal:  J Biol Chem       Date:  2015-09-10       Impact factor: 5.157

Review 3.  Controlling the master-upstream regulation of the tumor suppressor LKB1.

Authors:  Lars Kullmann; Michael P Krahn
Journal:  Oncogene       Date:  2018-03-15       Impact factor: 9.867

4.  PIM kinases inhibit AMPK activation and promote tumorigenicity by phosphorylating LKB1.

Authors:  Kwan Long Mung; William B Eccleshall; Niina M Santio; Adolfo Rivero-Müller; Päivi J Koskinen
Journal:  Cell Commun Signal       Date:  2021-06-30       Impact factor: 5.712

5.  PI3K/Akt/mTOR signaling & its regulator tumour suppressor genes PTEN & LKB1 in human uterine leiomyomas.

Authors:  Annu Makker; Madhu Mati Goel; Abbas Ali Mahdi; Vikram Bhatia; Vinita Das; Anjoo Agarwal; Amita Pandey
Journal:  Indian J Med Res       Date:  2016-05       Impact factor: 2.375

6.  Costunolide and dehydrocostuslactone combination treatment inhibit breast cancer by inducing cell cycle arrest and apoptosis through c-Myc/p53 and AKT/14-3-3 pathway.

Authors:  Zhangxiao Peng; Yan Wang; Jianhui Fan; Xuejing Lin; Chunying Liu; Yang Xu; Weidan Ji; Chao Yan; Changqing Su
Journal:  Sci Rep       Date:  2017-01-24       Impact factor: 4.379

7.  Tankyrase disrupts metabolic homeostasis and promotes tumorigenesis by inhibiting LKB1-AMPK signalling.

Authors:  Nan Li; Yifan Wang; Shinya Neri; Yuanli Zhen; Lon Wolf R Fong; Yawei Qiao; Xu Li; Zhen Chen; Clifford Stephan; Weiye Deng; Rui Ye; Wen Jiang; Shuxing Zhang; Yonghao Yu; Mien-Chie Hung; Junjie Chen; Steven H Lin
Journal:  Nat Commun       Date:  2019-09-25       Impact factor: 14.919

8.  Insulin-independent stimulation of skeletal muscle glucose uptake by low-dose abscisic acid via AMPK activation.

Authors:  Mirko Magnone; Laura Emionite; Lucrezia Guida; Tiziana Vigliarolo; Laura Sturla; Sonia Spinelli; Ambra Buschiazzo; Cecilia Marini; Gianmario Sambuceti; Antonio De Flora; Anna Maria Orengo; Vanessa Cossu; Sara Ferrando; Ottavia Barbieri; Elena Zocchi
Journal:  Sci Rep       Date:  2020-01-29       Impact factor: 4.379

9.  A-674563, a putative AKT1 inhibitor that also suppresses CDK2 activity, inhibits human NSCLC cell growth more effectively than the pan-AKT inhibitor, MK-2206.

Authors:  Paige M Chorner; Roger A Moorehead
Journal:  PLoS One       Date:  2018-02-22       Impact factor: 3.240

10.  Endothelial cell rearrangements during vascular patterning require PI3-kinase-mediated inhibition of actomyosin contractility.

Authors:  Ana Angulo-Urarte; Pedro Casado; Sandra D Castillo; Piotr Kobialka; Maria Paraskevi Kotini; Ana M Figueiredo; Pau Castel; Vinothini Rajeeve; Maria Milà-Guasch; Jaime Millan; Cora Wiesner; Helena Serra; Laia Muixi; Oriol Casanovas; Francesc Viñals; Markus Affolter; Holger Gerhardt; Stephan Huveneers; Heinz-Georg Belting; Pedro R Cutillas; Mariona Graupera
Journal:  Nat Commun       Date:  2018-11-16       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.